Home/Healthcare/Healthcare IT/UAE Continuous Glucose Monitoring (CGM) Market

UAE Continuous Glucose Monitoring (CGM) Market - Strategic Insights and Forecasts (2026-2031)

Forward-looking analysis of UAE continuous glucose monitoring technologies, healthcare modernization, and market growth.

$2,850
Single User License
Report OverviewSegmentationTable of ContentsCustomize Report

Report Overview

The UAE Continuous Glucose Monitoring market is forecast to grow at a CAGR of 12.5%, reaching USD 0.015 billion in 2031 from USD 0.008 billion in 2026.

UAE Continuous Glucose Monitoring (CGM) Market - Strategic Insights and Forecasts (2026-2031) market growth projection from $0.01B in 2026 to $0.01B by 2031 at a CAGR of 12.5%.
UAE Continuous Glucose Monitoring (CGM) Market - Strategic Insights and Forecasts (2026-2031) market growth projection from $0.01B in 2026 to $0.01B by 2031 at a CAGR of 12.5%.

Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.

Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.

Due to an increase in unhealthy lifestyles and other risk factors, diabetes is a fast-spreading illness that affects a significant portion of the population in the United Arab Emirates. The World Diabetes Federation estimates that the number of diabetics in the UAE would increase from 0.99 million in 2021 to 1.32 million in 2045. Individuals can reduce their risk of contracting this disease by adopting better lives and supporting expanding governmental measures. For patients hospitalized in hospitals with serious lung infections, controlling blood glucose levels become crucial. The patient's blood glucose levels significantly changed as a result of the disease-treating medications. Also, throughout the forecast period, segment growth is anticipated to be fueled by the rising need for effective drug treatments for the treatment of diabetes.

Growing prevalence of Type-1 and Type-2 diabetes to surge growth.

As there is an increase in diabetic patients, there is an increase in continuous glucose monitoring systems. Also, there are various conveniences in testing blood glucose levels because of additional variables including technological improvements. Continuous glucose monitoring devices are one such development in blood glucose level monitoring. As a result, the market is anticipated to expand as more people with type 2 and type 1 diabetes use monitoring devices.

Technological advancements to surge growth

Players in the global market are actively funding CGM research and technological development. The government's efforts to encourage local manufacturers to localize their production and to invite international companies in the healthcare sector to the nation assist the expansion of UAE continuous glucose monitoring devices. A further factor supporting the rise of the UAE glucometers market in the anticipated years is the general public's active investment in improved healthcare services and the need for modern monitoring tools that can help them maintain regular checks on their health issues.

Market Key Developments

  • In August 2022, an alliance between Al-Futtaim Health and Abbott has been launched to raise advanced laboratory diagnostic standards in Dubai.

  • In June 2022, The Dubai Branch of BD (Becton, Dickinson, and Company) (NYSE: BDX) and VPS Healthcare's Burjeel Medical City (BMC) today announced a strategic partnership that will allow both organizations to accelerate innovation and deliver healthcare excellence in the nation.

UAE Continuous Glucose Monitoring (CGM) Market Scope:

Report Metric Details
Total Market Size in 2026 USD 0.008 billion
Total Market Size in 2031 USD 0.015 billion
Forecast Unit bILLION
Growth Rate 12.5%
Study Period 2021 to 2031
Historical Data 2021 to 2024
Base Year 2025
Forecast Period 2026 – 2031
Segmentation Application, End-User Industry
Companies
  • Abbott Laboratories
  • Medtronic plc
  • Dexcom Inc.
  • Sanofi
  • Roche Diabetes Care Inc.

Market Segmentation

By Application
  • Diabetes Patients
  • Critical Patients
By End-User Industry
  • Hospitals
  • Diagnostic Centers & Clinics
  • Home Care

Table of Contents

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. UAE CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY APPLICATION

5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Patients

6. UAE CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY END-USER INDUSTRY

6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care

7. COMPETITIVE ENVIRONMENT AND ANALYSIS

7.1. Major Players and Strategy Analysis

7.2. Emerging Players and Market Lucrativeness

7.3. Mergers, Acquisitions, Agreements, and Collaborations

7.4. Vendor Competitiveness Matrix

8. COMPANY PROFILES 

8.1. Abbott Laboratories

8.2. Medtronic plc

8.3. Dexcom, Inc.

8.4. Sanofi

8.5. Roche Diabetes Care, Inc.

8.6. Insulet Corporation

8.7. Novo Nordisk A/S

8.8. Becton, Dickinson, and Company

UAE Continuous Glucose Monitoring (CGM) Market Report

Report IDKSI061614923
PublishedFeb 2026
Pages105
FormatPDF, Excel, PPT, Dashboard

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Frequently Asked Questions

The UAE Continuous Glucose Monitoring (CGM) market is forecast for significant expansion, projected to grow at a Compound Annual Growth Rate (CAGR) of 12.5% during the 2026-2031 period. This growth will see the market's value increase from USD 0.008 billion in 2026 to an estimated USD 0.015 billion by 2031.

Key drivers for the UAE CGM market include growing awareness of diabetes preventative care, the introduction of new products, and supportive government efforts. Additionally, the increasing prevalence of Type 1 and Type 2 diabetes, fueled by unhealthy lifestyles and other risk factors, significantly boosts the demand for CGM devices.

Continuous Glucose Monitoring (CGM) systems in the UAE have broad applications across various healthcare settings. These include hospital ICUs, diagnostic centers, and clinics. The technology is also applicable for all age groups and across different geographical locations, emphasizing its widespread utility in diabetes management.

The increasing prevalence of diabetes in the UAE is a major catalyst for the CGM market, driving significant demand for monitoring devices. The World Diabetes Federation estimates that the number of diabetics in the UAE will rise from 0.99 million in 2021 to 1.32 million by 2045. This surge in diabetic patients directly correlates with an increased need for continuous glucose monitoring systems for better disease management.

Technological advancements are a crucial growth driver for the UAE CGM market, as global players are actively investing in research and development to create novel and cutting-edge devices. These innovations enhance the convenience and effectiveness of monitoring blood glucose levels, leading to increased adoption among patients with Type 1 and Type 2 diabetes.

Government initiatives in the UAE are instrumental in fostering the CGM market by promoting diabetes preventative care and encouraging healthier lifestyles. These efforts also support local manufacturers and invite international companies in the healthcare sector, creating a robust environment for market expansion and increasing public awareness about diabetes management and CGM technology.

Need data specifically for your business?Request Custom Research β†’
Related Reports

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon